Logo image of CGIX

Cancer Genetics Inc (CGIX) Stock Price, Forecast & Analysis

USA - NASDAQ:CGIX -

4.61
-0.11 (-2.33%)
Last: 3/30/2021, 8:00:00 PM
4.63
+0.02 (+0.43%)
After Hours: 3/30/2021, 8:00:00 PM

CGIX Key Statistics, Chart & Performance

Key Statistics
Market Cap18.83M
Revenue(TTM)6.33M
Net Income(TTM)-4.53M
Shares4.08M
FloatN/A
52 Week High17.5
52 Week Low2.11
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.25
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A


CGIX short term performance overview.The bars show the price performance of CGIX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 60

CGIX long term performance overview.The bars show the price performance of CGIX in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30 40

The current stock price of CGIX is 4.61 null. In the past month the price decreased by -21.73%. In the past year, price increased by 45.89%.

Cancer Genetics Inc / CGIX Daily stock chart

CGIX Latest News, Press Relases and Analysis

About CGIX

Company Profile

Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey.

Company Info

Cancer Genetics Inc

201 ROUTE 17 NORTH 2ND FLOOR

RUTHERFORD NJ 07070

CEO: John A. Roberts

Phone: 201-528-9200

Cancer Genetics Inc / CGIX FAQ

Can you describe the business of Cancer Genetics Inc?

Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey.


Can you provide the latest stock price for Cancer Genetics Inc?

The current stock price of CGIX is 4.61 null. The price decreased by -2.33% in the last trading session.


Does CGIX stock pay dividends?

CGIX does not pay a dividend.


How is the ChartMill rating for Cancer Genetics Inc?

CGIX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Which stock exchange lists CGIX stock?

CGIX stock is listed on the Nasdaq exchange.


Would investing in Cancer Genetics Inc be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CGIX.


CGIX Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to CGIX. When comparing the yearly performance of all stocks, CGIX is one of the better performing stocks in the market, outperforming 76.32% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CGIX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CGIX. Both the profitability and financial health of CGIX have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CGIX Financial Highlights

Over the last trailing twelve months CGIX reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS increased by 60.44% compared to the year before.


Industry RankSector Rank
PM (TTM) -71.5%
ROA -46.7%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-81.25%
Sales Q2Q%-24.21%
EPS 1Y (TTM)60.44%
Revenue 1Y (TTM)631.68%

CGIX Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

CGIX Ownership

Ownership
Inst Owners8.92%
Ins Owners131.66%
Short Float %N/A
Short RatioN/A